Press Releases
Page 12 • 12 itemsAccess critical pharma & biotech press releases. Stay ahead on drug approvals, clinical trials, M&A, and regulatory updates impacting global markets.
TME Pharma NOX-A12 Triple Therapy Shows Promise in Brain Cancer GLORIA Trial Published in Nature Communications
TME Pharma announces Nature Communications publication of NOX-A12 triple therapy Phase 1/2 GLORIA trial results for brain cancer treatment.
New Additional Risk Minimization Measures (aRMMs) Training Course Launches to Enhance Pharmaceutical Patient Safety Protocols
PharSafer Associates launches comprehensive aRMMs training course focusing on regulatory frameworks and patient safety evaluation strategies for pharma professionals.
Healthcare Logistics Market to Surge $159.91 Billion by 2030, Driven by Biopharmaceutical Growth and Cold Chain Expansion
Global healthcare logistics market projected to grow $159.91 billion from 2025-2030 with 14.4% CAGR, driven by biopharmaceutical expansion and cold chain demands.
Medical Device Software Compliance Training Launches for EU MDR, IVDR and FDA Regulations in June 2026
New online training course addresses critical medical device software compliance requirements under EU MDR, EU IVDR, and FDA regulations starting June 22-26, 2026.
ONWARD Medical Raises €40 Million in Capital Increase Led by EQT Life Sciences for Spinal Cord Stimulation Technology
ONWARD Medical secures €40M funding with €25M from EQT Life Sciences to advance spinal cord stimulation therapies for paralysis and movement disorders.
SAHPRA and African Medicines Agency Launch Continental Pharmaceutical Regulatory Harmonization Course for May 2026
SAHPRA partners with African Medicines Agency for comprehensive regulatory affairs course covering continental harmonization and product registration.
Bavarian Nordic's VIMKUNYA Chikungunya Vaccine Receives First Swiss Approval from Swissmedic
Bavarian Nordic receives Swissmedic approval for VIMKUNYA, the first chikungunya vaccine approved in Switzerland for individuals 12 years and older.
Seragon's SRN-901 Longevity Drug Shows Significant Lifespan Extension in Preclinical Study
Seragon Biosciences' SRN-901 demonstrated significant lifespan and healthspan extension in mice, marking a breakthrough in longevity therapeutics development.
Boehringer Ingelheim and Zai Lab Launch Phase Ib/II Trial for DLL3-Targeting Combination Therapy in Small Cell Lung Cancer
Boehringer Ingelheim partners with Zai Lab to test obrixtamig plus zocilurtatug pelitecan combination in Phase Ib/II trial for SCLC and neuroendocrine carcinomas.
IMVT-1402 and 7 Other Late-Stage Drugs Transform Generalized Myasthenia Gravis Treatment Pipeline in 2026
Eight promising late-stage drugs including IMVT-1402 from Immunovant signal breakthrough era for generalized myasthenia gravis patients with novel mechanisms.
Drug Development Services Market Surges to $31.5 Billion in 2026, Driven by Pharmaceutical R&D Investments
Drug development services market grows 12.2% CAGR to reach $31.5 billion in 2026, fueled by increased pharmaceutical R&D spending and outsourcing trends.
Medicenna's Bizaxofusp Shows Promise in Brain Cancer Trials Ahead of 2026 Investor Conference
Medicenna's bizaxofusp demonstrates clinical progress in glioblastoma trials with FDA FastTrack status, positioning for major investor presentation in 2026.